Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Capecitabine in Nasopharyngeal Carcinoma
NCT07238569Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 3 trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07238569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238569.